Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$-0.60
EPS est.
$-0.53
EPS surprise
-12.78%
1-day move
+2.20%
Natera's earnings report showed a larger-than-expected loss per share, which may raise concerns among investors about profitability. However, the stock reacted positively, increasing by 2.20%. This could indicate that investors are looking beyond the EPS miss, possibly focusing on other aspects of the company's performance or future potential.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.60 | $-0.55 | -12.78% |
| Revenue | — | $617M | — |
No transcript is on record, and the analysis is based on numerical results only.
Natera, Inc. is a biotechnology company focused on genetic testing and diagnostics. With a market cap of $31 billion, it plays a significant role in the healthcare sector, particularly in prenatal testing and oncology, which are growing areas of interest in personalized medicine.
Last quarter
In Q4 2025, Natera reported an EPS of $-1.52, significantly missing expectations. The stock reacted positively the following day, gaining 2.02%.
EPS beat streak
0Q
EPS beat rate
38%
Avg EPS surprise
-32.20%
Avg 1-day reaction
+0.28%
Analysts expect Natera to report a narrower loss this quarter, with revenue growth being a focal point. The market is cautiously optimistic but remains wary due to past misses.
Bull case
If Natera can beat EPS estimates and show strong revenue growth, it could signal a turnaround in its financial performance, boosting investor confidence.
Bear case
On the other hand, if the company fails to meet expectations again, it could raise concerns about its growth prospects and lead to further stock declines.
Key metrics to watch
EPS
$-0.55Earnings per share (EPS) is a key indicator of profitability, and investors will be looking to see if Natera can narrow its losses this quarter.
Revenue
$617MRevenue growth is crucial for Natera as it reflects demand for its genetic testing services and overall business health.
The print will turn on these.
Q1
Can Natera achieve revenue of at least $617M this quarter?
Meeting or exceeding this revenue target will be crucial for demonstrating growth and restoring investor confidence.
Q2
Will the EPS come in better than the consensus estimate of $-0.55?
A narrower loss could indicate improved operational efficiency and market demand, which is vital for the stock's performance.
—
Est. EPS
$0.97
Est. Rev
$754M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus may underestimate Natera's ability to leverage new testing technologies that could drive revenue growth beyond expectations this quarter.
Supporting evidence
The stock has shown resilience with positive movements following earnings surprises in the past.
Options pricing suggests that traders are expecting a larger move than historical averages, indicating potential for a surprise.
Natera's recent focus on expanding its testing portfolio could yield better-than-expected results.
Key risk
If revenue exceeds $633M, it could significantly shift market sentiment in favor of Natera.
Pre-commit to what would confirm each case.
The market is weighing whether Natera can recover from previous earnings misses and show signs of sustainable growth.
Bull confirmed if
Revenue growth exceeding $617M with EPS better than $-0.55 would confirm the bull case.
Bear confirmed if
An EPS worse than $-0.68 and revenue below $584M would confirm the bear case.
What the market is pricing for the move.
Implied Move
±16.14%
Historical Avg
±1.9%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±16.1% while NTRA has averaged ±1.9% over the last 8 prints — setup is pricing rich.
ATM IV
1.2%
30d HV
57.5%
Smart-money positioning from the most recent 13F filings.
Institutional
96.75%
of float
Insider
2.74%
of float
Holders
1,196
institutions
Top Holders· as of Jun 2026
JPMORGAN CHASE & CO
12,865,346 sh · $5.1B
8.93%
-3.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Natera beats expectations, history suggests a potential stock increase of around +1.43%, confirming a positive turnaround narrative.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await clearer guidance.
Miss
A miss could lead to a decline in stock price, with history suggesting an average drop of around +1.14% following such outcomes.
The lines on the call that would change the story.
Blackrock Inc.
10,914,608 sh · $4.3B
7.57%
2.2%
Price (T.Rowe) Associates Inc
9,021,895 sh · $3.6B
6.26%
-26.0%
Vanguard Capital Management LLC
6,228,216 sh · $2.5B
4.32%
3.7%
Vanguard Portfolio Management LLC
5,782,640 sh · $2.3B
4.01%
2.4%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.